Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol INCY
Incyte
INCY
73
$62.11arrow_drop_down0.92%-$0.58
S&P500

Performance History

Chart placeholder
Key Stats
Open$62.28
Prev. Close$62.69
EPS3.3
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$12.79B
PE Ratio18.82
LOWHIGH
Day Range61.42
63.08
52 Week Range50.27
67.36
Ratios
P/B Ratio2.33
Revenue$3.69B
Operating M. %10.47%
Earnings$597.59M
Earnings Growth %75.42%
EBITDA Margin %21.69%
ROE %15.13%
EPS3.3

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About Incyte (INCY)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Herve Hoppenot
Headquarters
Wilmington
Employees
2324
Exchange
NASDAQ
add Incyte to watchlist

Keep an eye on Incyte

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Incyte's (INCY) price per share?

The current price per share for Incyte (INCY) is $62.11. The stock has seen a price change of -$0.58 recently, indicating a -0.93% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Incyte (INCY)?

For Incyte (INCY), the 52-week high is $67.36, which is 8.45% from the current price. The 52-week low is $50.27, the current price is 23.55% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Incyte (INCY) a growth stock?

Incyte (INCY) has shown an average price growth of 0.41% over the past three years. It has received a score of 32 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Incyte as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Incyte (INCY) stock price performance year to date (YTD)?

As of the latest data, Incyte (INCY) has a year-to-date price change of -5.1%. Over the past month, the stock has experienced a price change of 8.87%. Over the last three months, the change has been 6.41%. Over the past six months, the figure is -0.3%. Looking at a longer horizon, the five-year price change stands at -24.11%.

help
Is Incyte (INCY) a profitable company?

Incyte (INCY) has a net income of $597.6M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.1% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 10.47% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $3.7B, with a revenue growth rate of 8.87%, providing insight into the company's sales performance and growth. The gross profit is $3.44B. Operating income is noted at $620.52M. Furthermore, the EBITDA is $979.82M.

help
What is the market capitalization of Incyte (INCY)?

Incyte (INCY) has a market capitalization of $12.8B. The average daily trading volume is 7.51M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level